Predictive Technology Group, Inc. (PRED) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Salt Lake City, UT, United States. Le PDG actuel est Bradley C. Robinson.
PRED a date d'introduction en bourse 2008-01-02, 62 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $89.88K.
Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
